U.S. markets open in 32 minutes
  • S&P Futures

    3,839.75
    +11.75 (+0.31%)
     
  • Dow Futures

    31,310.00
    -61.00 (-0.19%)
     
  • Nasdaq Futures

    12,946.50
    +114.75 (+0.89%)
     
  • Russell 2000 Futures

    2,197.80
    -2.20 (-0.10%)
     
  • Crude Oil

    62.43
    -1.10 (-1.73%)
     
  • Gold

    1,762.00
    -13.40 (-0.75%)
     
  • Silver

    26.84
    -0.84 (-3.03%)
     
  • EUR/USD

    1.2124
    -0.0062 (-0.51%)
     
  • 10-Yr Bond

    1.4580
    -0.0600 (-3.95%)
     
  • Vix

    27.79
    +6.45 (+30.22%)
     
  • GBP/USD

    1.3951
    -0.0062 (-0.45%)
     
  • USD/JPY

    106.3330
    +0.1030 (+0.10%)
     
  • BTC-USD

    46,469.90
    -4,503.06 (-8.83%)
     
  • CMC Crypto 200

    927.99
    -5.15 (-0.55%)
     
  • FTSE 100

    6,540.59
    -111.37 (-1.67%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

A live webcast of the third quarter financial results may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the third quarter financial results webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005046/en/

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com